Immunization with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) according to different schedules in infants in South Africa: a phase III trial
Background: Limited clinical data exists to assess differences between various infant pneumococcal conjugate vaccine schedules. In this trial, we evaluated immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) administered using 3 diff...
Main Authors: | Shabir A Madhi, Anthonet Koen, Lisa Jose, Marta Moreira, Nadia van Niekerk, Clare Cutland, Nancy François, Javier Ruiz-Guiñazú, Juan Pablo Yarzabal, Dorota Borys, Lode Schuerman |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2017-06-01
|
Series: | Expert Review of Vaccines |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/14760584.2017.1321990 |
Similar Items
-
Safety profile of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV)
by: Sven Arne Silfverdal, et al.
Published: (2017-02-01) -
Immunogenicity and safety of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Taiwan
by: Tzou-Yien Lin, et al.
Published: (2012-09-01) -
A 6-year safety surveillance of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in South Korea
by: Soon Min Lee, et al.
Published: (2018-12-01) -
Effectiveness and impact of the 10-valent pneumococcal conjugate vaccine, PHiD-CV: review of clinical trials and post-marketing experience
by: Tomas Mrkvan, et al.
Published: (2018-09-01) -
Estimated public health impact of human rotavirus vaccine (HRV) and pneumococcal polysaccharide protein D-conjugate vaccine (PHiD-CV) on child morbidity and mortality in Gavi-supported countries
by: Alen Marijam, et al.
Published: (2022-12-01)